Iterum Therapeutics plc (ITRMF) Accounts Payables (2017 - 2025)

Iterum Therapeutics has reported Accounts Payables for 9 years, with the latest figure at $577000.0 in Q3 2025.

• On a quarterly basis, Accounts Payables fell 30.9% year-over-year to $577000.0 in Q3 2025; TTM through Sep 2025 was $577000.0, a 30.9% decrease from a year earlier, with the FY2024 full-year figure at $251000.0, down 94.98% from the prior year.
• Accounts Payables was $577000.0 for Q3 2025 at Iterum Therapeutics, down from $1.2 million in the prior quarter.
• The five-year high for Accounts Payables was $5.5 million in Q3 2023, with the low at $251000.0 in Q4 2024.
• Average Accounts Payables over 5 years is $1.8 million, with a median of $1.2 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables soared 372.05% in 2023, then sank 94.98% in 2024.
• Over 5 years, Accounts Payables stood at $878000.0 in 2021, then soared by 215.95% to $2.8 million in 2022, then jumped by 80.1% to $5.0 million in 2023, then tumbled by 94.98% to $251000.0 in 2024, then jumped by 129.88% to $577000.0 in 2025.
• The last three Accounts Payables figures came in at $577000.0 (Q3 2025), $1.2 million (Q2 2025), and $413000.0 (Q1 2025), per Business Quant data.